VIDEO: Novel IL-23 inhibitor induces remission in moderate-to-severe Crohn’s disease

SAN DIEGO — In this exclusive video from DDW, Brian Feagan, MD, from Robarts Clinical Trials, London, Ontario, Canada, discusses positive results from a phase 2 randomized controlled trial of the novel selective IL-23 inhibitor risankizumab (formerly BI-655066) in moderate-to-severe active Crohn’s disease.

“This was conducted in a very refractory patient population; 94% of patients had actually received TNF-blocker therapy and had failed or were intolerant to those drugs,” Feagan said. “At week 12 what we saw in the pooled group — the 200 mg and 600 mg [groups] taken together— was [the] overall rate of remission was approximately 30% vs. 15% [with placebo], which was statistically significant. But perhaps more importantly, the high dose of the drug ... was approximately 36%, and there was a dose-response curve where the low dose was intermediate between placebo and the high dose. So, a very clear proof-of-concept, with dose-linearity of response ... about as good as you can get in a phase 2 study.”

Reference:

Feagan BG, et al. Abstract #812a. Presented at: Digestive Disease Week; May 21-24, 2016; San Diego.

Disclosures: Feagan reports numerous financial relationships, including AbbVie and Boehringer-Ingelheim. Please see the DDW disclosure list for all other researchers’ relevant financial disclosures.